Aileron Therapeutics, Inc. (ALRN) EPS Estimated At $-0.52

July 13, 2018 - By Richard Doty

Analysts expect Aileron Therapeutics, Inc. (NASDAQ:ALRN) to report $-0.52 EPS on August, 9.They anticipate $0.07 EPS change or 15.56 % from last quarter’s $-0.45 EPS. After having $-0.52 EPS previously, Aileron Therapeutics, Inc.’s analysts see 0.00 % EPS growth. The stock increased 1.93% or $0.09 during the last trading session, reaching $5.02. About 29,439 shares traded. Aileron Therapeutics, Inc. (NASDAQ:ALRN) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing a novel class of therapeutics in the United States. The company has market cap of $73.98 million. The company??s lead product includes ALRN-6924, a stapled peptide that in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial for the treatment of peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia and advanced myelodysplastic syndrome (MDS); and Phase II b trial for the treatment of AML/MDS in combination with cytosine arabinoside. It currently has negative earnings. It is also developing next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.